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tion was built (Tableau 8) to visualize the information to be easily communicated to 
local authorities and clinicians. Results: A middle-sized Finnish municipality with 
74 168 inhabitants (Joensuu) was chosen as a case-example. The estimated num-
ber of diabetic patients was 2267, out of which 1678 had T2D. Within three years 
among patients with T2D, the predicted number of CHD events would be 73 and 
57 for HbA1c levels 6.5% and 8.0%, respectively, resulting total of 16 avoidable CHD 
events. ConClusions: By bringing the understanding of epidemiology and treat-
ment effects to local level, there is a possibility to show the positive outcomes of good 
diabetes care in real practice. This information may be used to help budget holders 
in resource allocation and to motivate authorities, clinicians (and patients) to follow 
the diabetes treatments guidelines.
PDB19
Results fRom a two-stage DelPhi PRocess to iDentify 
caRDiometaBolic Risk factoRs in aDRenal insufficiency Patients anD 
unDeRstanD cuRRent tReatment in italy
Elvidge J.1, Anelli M.2, Lee D.1, Marelli C.3, Teneishvili M.4
1BresMed, Sheffield, UK, 2Keypharma srl, Milan, Italy, 3ViroPharma SPRL, Maidenhead, UK, 
4ViroPharma LTD., Maidenhead, UK
objeCtives: To obtain information regarding the presence of cardiometabolic risk 
factors among adrenal insufficiency (AI) patients in Italy. To understand treatment 
patterns and goals and to gain consensus regarding how effectively existing therapies 
meet these goals. Methods: A two-stage Delphi process was conducted with four 
Italian key opinion leaders (KOLs). Each KOL completed an electronic survey eliciting 
information regarding AI management and the prevalence and importance of risk 
factors. To reach a consensus on the key issues, the results were discussed at a face-
to-face meeting. Results: The KOLs agreed that avoiding adrenal crisis is the main 
treatment goal, and that quality of life and avoiding fatigue are most important to 
patients. Patients typically receive 20–30 mg cortisone acetate or hydrocortisone daily 
in 2-3 administrations. A consensus was reached that cardiometabolic risk factors 
are not hallmarks of AI, but are related to its glucocorticoid replacement treatment 
(GC) either due to overtreatment or non-physiological replacement of serum cortisol. 
In agreement with the available evidence in the literature they suggested that the 
increase risk may be associated with the non-physiological cortisol peaks and troughs 
that are characteristic of the existing GC replacement therapies. They established that 
50% of AI patients are over treated, often to minimise the risk of adrenal crisis and all 
patients currently face non-physiological cortisol replacement, given the available 
treatments. GC replacement–related risks included (prevalence in AI in parenthe-
ses): hypertension (10–30%), abdominal obesity (15–35%), dyslipidaemia (33%) and 
metabolic syndrome (30–35%). ConClusions: The prevalence of cardiometabolic 
risk factors is associated with the treatment of AI, not AI itself. Over-treatment and 
non-physiological cortisol replacement may explain cardiometabolic risks. A physi-
ological alternative to existing treatments would be welcomed in Italy.
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objeCtives: Type 2 Diabetes mellitus (T2DM) is becoming a major chronic disease 
burden worldwide. Indians are known to have an increased predisposition for diabetes 
which has become an important health concern. The current analysis is aimed to 
systematically review medical literature on T2DM, its prevalence and complications in 
India and also explore the differential risk factors in sub-groups. Methods: Studies 
are being retrieved from Pubmed, Cochrane and Embase databases using relevant 
search strategies. Search limits are: articles in English, in human adults and published 
since year 2001. Pre-specified inclusion/exclusion criteria will identify study types, 
such as randomized controlled trials (RCTs), observational and retrospective studies 
reporting incidence/prevalence, risk factors and complications of T2DM patients in 
India. Two researchers will independently extract the data and analysis of comparable 
outcomes will be carried out as per appropriate statistics along with critical appraisal 
of the studies. Meta-analysis will be done using RevMan (v5.0) Results: Though 
there have been several studies assessing incidence/prevalence, complications and 
risk factors for T2DM, a systematic review/meta-analysis of the evidence is lacking 
in the Indian scenario. This study aims to provide the much-needed evidence link-
ing incidence/prevalence, complication and risk factors in different groups of T2DM 
patients. This study hopes to demonstrate association of various risk factors with 
disease progression and with complications of T2DM. ConClusions: The prevalence 
of T2DM has been increasing over the years. The data from published studies will 
hopefully answer some of the prevailing variations and trends in prevalence of T2DM 
between different subgroups of T2DM patients and their association with risk factors.
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objeCtives: To review lifestyle and genetic factors during pregnancy and early child-
hood in South Asian population living in Europe that may influence later risks of 
insulin resistance, metabolic syndrome, T2DM and CVD Methods: A systematic 
search, using controlled and free terms (i.e.- metabolic-syndrome, glucose-intol-
erance, diabetes-mellitus, pregnancy, foetal development, life-style, nutrition) was 
conducted in Medline, Centre for Reviews and Dissemination and Cochrane Library 
databases. It was completed by pearling and hand-searching. Two reviewers assessed 
independently the results retrieved in the search, to adopt a decision on inclusion/
exclusion. The quality of included papers was appraised with STROBE checklist for 
than the non-AI population. Since the comparison was unmatched, results should be 
interpreted with caution. Ongoing analysis will include a detailed data assessment, 
with a stronger comparison against matched non-AI populations.
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objeCtives: To estimate the cumulative incidence and cost of cardiovascular (CV) 
complications (stroke, acute coronary syndrome (ACS), acute heart failure (AHF) 
and peripheral vascular disease (PVD)) leading to hospitalization in T2D patients 
with a CV complication history in France. Methods: We conducted an analysis of 
the Program for a Medicalized Information System (PMSI) databases which record 
all hospitalizations occurring in France including rehabilitation care. We identi-
fied all patients with a T2D diagnosis and hospitalized for any reason in 2006-2008 
and selected patients with a documented CV complication history. We analyzed 
those patients as a retrospective cohort followed-up for 3 years from the index 
date (January 1st 2009) and calculated cumulative incidences of new CV complica-
tions. We considered death as a competing event. Mean hospital and rehabilitation 
costs were based on the National Scale of Costs. Results: A total of 1,114,182 T2D 
patients were hospitalized in France in 2006-2008. Among them, 30.5% (n= 339,328) 
had a CV complication history. Mean age was 70.6 (+/-11.1), and 61.9% were males. 
Hypertension, dyslipidemia, renal impairment and obesity were reported in 
80.1%, 45.0%, 33.3% and 29.2% of the patients, respectively. The 3-year cumulative 
incidences for one or more new CV complication were: 3.6% [95%CI:3.5%;3.7%] for 
stroke, 5.6% [95%CI:5.5%;5.7%] for ACS, 6.8% [95%CI:6.7%;6.9%] for AHF and 15.0% 
[95%CI:14.9%;15.1%] for PVD with a mean cost per event of € 5,724, € 5 315, € 4 726, € 4 
766, respectively. 21.8%, 10.5%, 11.4% and 9.5% of patients required rehabilitation 
care for stroke, ACS, AHF and PVD, at an additional mean cost of € 12,000, € 6 233, € 6 
987 and € 9 219 per patient, respectively. ConClusions: CV complications represent 
an important burden for T2D patients and the health system in France. These results 
would be helpful for health technology assessment and for economic evaluation of 
upcoming interventions which reduce CV risk in T2D patients.
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objeCtives: While concerning to diabetic treatment, any suboptimum therapy may 
lead to medication error (ME). Objective of study was to report the causes, severity, 
increase in cost of therapy and outcomes of ME in patients undergone treatment for 
diabetes in medicine ward of a community hospital. Methods: Prospective obser-
vational study (8 months). In-patients with type-II diabetes mellitus were chosen 
randomly and the details were followed till discharge. Results: Incidences of 504 
MEs were observed in 164 out of total patient pool of 230. The notable trends in MEs 
identified were- erroneous prescriptions 101(20.03%), inappropriate dosage-form 
93(18.4%), incorrect-route 63 (12.5%), incident of drug interactions 129 on 55 patients 
(10.09%), failure to monitor lab levels 27(5.30%), failure to adjust doses according to 
lab levels 37(7.14%) and 21(4.16%) cases of incorrect-indications. On severity scale, 
MEs were classified as 143(28.37%) severe, 256(50.79%) moderate and 105(20.8%) mild. 
Predicted error outcome of 164 incidences which were reaches to patient classified 
as- no serious 85(51.8%), moderately serious 61(37.19%), 9(5.3%) life threatening and 
9(5.35%) death (predicted). We observed fair degree of linear correlation between 
increasing age and occurrence of ME 0.99 (rcritical value-0.878). Female sex was found 
to be at higher risk of MEs than male (X2= 6.73, P-value= 0.01). There was a linear 
correlation observed between the polypharmacy and ME 0.95 ( rcriticalvalue-0.44). It 
was observed that, out of total 129 drug interactions identified; only 35(27.13%) were 
moderate, while 72(55.81%) were severe and 22(17.05%) found mild. Significant incre-
ment in the length of stay in hospital and direct drug cost were observed among the 
severe, moderately severe and in mild cases. ConClusions: The observed finding 
of ME defines specific clinical domains and patient subgroups for which aggressive 
efforts needed to reduce MEs. Through information dissemination and education, 
managed health care professionals should play more active role in ME-reduction.
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objeCtives: Type 2 diabetes (T2D) and its consequences are largely studied world-
wide. The number of diabetic patients is increasing and thus, a growing number 
of health care resources are needed to cover the treatment of this population. It is 
also known that in spite of the national treatment guidelines, the recommended 
HbA1c level (< 6.5%/48 mmol/mol) is not always achieved. In order to allocate the 
resources effectively, local information concerning epidemiological and demographic 
differences across different jurisdictions must be available. Methods: A national 
population-based study (Finriski 2007) was used to estimate the prevalence of dia-
betes in different geographical areas. The estimated prevalence rates and number 
of T2D patients were extrapolated to municipal level using demographic data from 
the official statistics. UKPDS risk equation was used to predict the number of cardio-
vascular events with and without proper treatment in each municipality. Local risk 
profile and different HbA1c levels (6.5% (48 mmol/mol) and 8.0% (64 mmol/mol)) were 
used to illustrate the importance of treating patients to target. A map-based applica-
